Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Exact Sciences Cor (EXAS)

Exact Sciences Cor (EXAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,980,604
  • Shares Outstanding, K 129,832
  • Annual Sales, $ 876,290 K
  • Annual Income, $ -83,990 K
  • 60-Month Beta 1.36
  • Price/Sales 15.21
  • Price/Cash Flow N/A
  • Price/Book 17.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.64
  • Number of Estimates 8
  • High Estimate -0.24
  • Low Estimate -0.82
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.05 +16.19%
on 01/27/20
103.22 -3.14%
on 02/20/20
+14.08 (+16.39%)
since 01/21/20
3-Month
75.35 +32.69%
on 11/22/19
105.56 -5.29%
on 01/10/20
+20.96 (+26.52%)
since 11/21/19
52-Week
75.35 +32.69%
on 11/22/19
123.99 -19.36%
on 07/30/19
+16.70 (+20.05%)
since 02/21/19

Most Recent Stories

More News
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 1.38% Rise

Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $99.72 to a high of $101.46. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of...

EXAS : 99.98 (-2.59%)
Bull of the Day: Guardant Health (GH)

Bull of the Day: Guardant Health (GH)

UNH : 301.43 (-0.23%)
NVTA : 23.10 (-3.02%)
GH : 88.81 (+1.59%)
EXAS : 99.98 (-2.59%)
BIIB : 336.71 (+0.02%)
AMGN : 222.79 (+0.29%)
Watch for Exact Sciences to Potentially Rebound After Falling 3.38% Yesterday

Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $91.61 to a high of $95.12. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $92.88...

EXAS : 99.98 (-2.59%)
Global Molecular Diagnostics Market (2019 to 2026) - Featuring Abbott Laboratories, Biomrieux, Danaher Corporation & Exact Sciences Corporation Among Others - ResearchAndMarkets.com

The "Molecular Diagnostics Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

ABT : 87.45 (-1.14%)
EXAS : 99.98 (-2.59%)
Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.

SYK : 224.30 (-0.08%)
ARAY : 3.32 (-1.48%)
RMD : 173.88 (-1.20%)
EXAS : 99.98 (-2.59%)
Exact Sciences: 4Q Earnings Snapshot

MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported fourth-quarter net income of $77.9 million, after reporting a loss in the same period a year earlier.

EXAS : 99.98 (-2.59%)
5 Earnings All-Stars with Spectacular Charts

These 5 companies have near perfect earnings surprise track records and their charts are a sight to behold.

CSCO : 46.29 (-1.18%)
AMAT : 64.27 (-3.21%)
CME : 208.83 (-0.08%)
EXAS : 99.98 (-2.59%)
SHOP : 520.66 (-2.79%)
Exact Sciences Announces Fourth-Quarter 2019 Results

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $295.6 million for the fourth quarter ended Dec. 31, 2019 and $876.3 million for the full year ended Dec. 31, 2019,...

EXAS : 99.98 (-2.59%)
Should Growth Investors Buy this Cancer Screening Biotech Stock?

Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

RGEN : 98.11 (-2.98%)
EXAS : 99.98 (-2.59%)
MRNA : 18.23 (-1.67%)
GH : 88.81 (+1.59%)
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EXAS : 99.98 (-2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade EXAS with:

Business Summary

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in...

See More

Key Turning Points

2nd Resistance Point 103.59
1st Resistance Point 101.79
Last Price 99.98
1st Support Level 98.79
2nd Support Level 97.59

See More

52-Week High 123.99
Fibonacci 61.8% 105.41
Last Price 99.98
Fibonacci 50% 99.67
Fibonacci 38.2% 93.93
52-Week Low 75.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar